Objective: To observe the preventing and treating effect of Salvia Miltiorrhiza Compsita (SMC) in patients with ischemic coronary heart disease (CHD) undergoing non heart surgery. Methods: One hundred and eight pati...Objective: To observe the preventing and treating effect of Salvia Miltiorrhiza Compsita (SMC) in patients with ischemic coronary heart disease (CHD) undergoing non heart surgery. Methods: One hundred and eight patients were randomly divided into control group and treatment group. During operation,the control group was treated by heteropathy such as nitrate ester, while the treatment group was treated with SMC intravenously. ECG, heart rate (HR), mean arterial pressure (MAP) and sphygmous blood oxygen saturation (SpO 2) and quantity of blood loss were observed during and at the end of the operation. The efficacy of treatment was judged according to the change of ECG. Results: The total effective rate in the treatment group was 90.7% (49/54 cases), while in the control group it was 35.2% (19/54 cases). There was significant difference between the two groups ( P <0.01). HR of the patients in the treatment group was not changed significantly, but in the control group, it became faster ( P <0.05). No significant difference was found in MAP and SpO 2 between the two groups, or in comparison of data before and after operation. Also no significant difference in quantity of blood loss was shown between the two groups. Conclusion: SMC could effectively protect heart function from myocardial ischemia in patients with CHD undergoing non heart surgery, neither shows any side effect. Therefore, it is an effective and safe measure.展开更多
文摘Objective: To observe the preventing and treating effect of Salvia Miltiorrhiza Compsita (SMC) in patients with ischemic coronary heart disease (CHD) undergoing non heart surgery. Methods: One hundred and eight patients were randomly divided into control group and treatment group. During operation,the control group was treated by heteropathy such as nitrate ester, while the treatment group was treated with SMC intravenously. ECG, heart rate (HR), mean arterial pressure (MAP) and sphygmous blood oxygen saturation (SpO 2) and quantity of blood loss were observed during and at the end of the operation. The efficacy of treatment was judged according to the change of ECG. Results: The total effective rate in the treatment group was 90.7% (49/54 cases), while in the control group it was 35.2% (19/54 cases). There was significant difference between the two groups ( P <0.01). HR of the patients in the treatment group was not changed significantly, but in the control group, it became faster ( P <0.05). No significant difference was found in MAP and SpO 2 between the two groups, or in comparison of data before and after operation. Also no significant difference in quantity of blood loss was shown between the two groups. Conclusion: SMC could effectively protect heart function from myocardial ischemia in patients with CHD undergoing non heart surgery, neither shows any side effect. Therefore, it is an effective and safe measure.
